HBIOHealthcare · Medical Instruments & SuppliesThe 2 Wall Street analysts covering Harvard Bioscience, Inc. hold a median 12-month price target of $7.5 — -5.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 19 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Harvard Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Volatility (31): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −5.7% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Benchmark | Maintains | Speculative Buy | $6.00 → $7.50 |
| 16 Mar 2026 | Benchmark | Maintains | Speculative Buy | $0.60 → $6.00 |
| 16 Mar 2026 | Benchmark | Maintains | Speculative Buy | — |
| 13 Mar 2026 | Benchmark | Maintains | Speculative Buy | $2.00 → $0.60 |
| 13 Mar 2026 | Benchmark | Maintains | Speculative Buy | — |
| 10 Sept 2025 | Benchmark | Maintains | Speculative Buy | — |
| 13 May 2025 | Benchmark | Maintains | Speculative Buy | — |
| 9 Apr 2025 | Keybanc | Downgrade | Sector Weight | — |
| 8 Apr 2025 | Keybanc | Downgrade | Sector Weight | — |
| 24 Mar 2025 | Benchmark | Maintains | Speculative Buy | — |
| 22 June 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 26 Apr 2023 | Benchmark | Maintains | Buy | — |
| 26 Apr 2023 | Keybanc | Maintains | Overweight | — |
| 10 Mar 2023 | Benchmark | Reiterates | Buy | — |
| 9 Nov 2022 | Keybanc | Maintains | Overweight | — |
| 5 Aug 2022 | Keybanc | Maintains | Overweight | — |
| 10 Nov 2020 | Keybanc | Initiates | Overweight | — |
| 10 Nov 2020 | KeyBanc | Initiates | Overweight | — |
| 27 Feb 2020 | Benchmark | Maintains | Speculative Buy | — |
| 17 Nov 2016 | Singular Research | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HBIO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Harvard Bioscience, Inc. returned +65.6% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 85% of US stocks
Cheaper than 21% of US stocks
Cheaper than 38% of US stocks
Higher than 55% of US stocks
Higher than 49% of US stocks
Higher than 69% of US stocks
Higher than 29% of US stocks
Higher than 19% of US stocks
Higher than 15% of US stocks
Higher than 56% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Harvard Bioscience, Inc. has a market value of $36.2M and an enterprise value of $73.9M.
Free cash flow in the twelve months to 30 June 2026: −$1.8M, after $713K of capital spending.
Trailing P/E: −0.6×; forward P/E: 12.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Harvard Bioscience, Inc. employs 316 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Harvard Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Harvard Bioscience, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the transcript of the event.
Why it matters — The earnings call transcript provides HBIO watchers with direct insight into the company's latest financial results and management's outlook.
Harvard Bioscience, Inc. announced it will release its second quarter 2026 financial results before the market opens on August 11, 2026, and will hold a conference call at 8:00 a.m. ET that same day to discuss the results.
Why it matters — Shareholders and analysts monitoring HBIO will look to the earnings call for an update on the company's financial performance and outlook for the quarter ended June 30, 2026.
The 2 Wall Street analysts covering Harvard Bioscience, Inc. have a median 12-month price target of $7.5, with estimates ranging from $7.5 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Harvard Bioscience, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Harvard Bioscience, Inc. 98 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Harvard Bioscience, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies -5.7% from the last close, and Ticker Nerd's factor model ranks Harvard Bioscience, Inc. 98 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Harvard Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.5 to $7.5 over the next 12 months.
Harvard Bioscience, Inc. returned +65.6% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Harvard Bioscience Inc. is a life sciences tools and instruments company that develops, manufactures, and sells technologies, products, and services used in research, discovery, and preclinical testing.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript". Harvard Bioscience, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the transcript of the event.
Harvard Bioscience Inc. is a life sciences tools and instruments company that develops, manufactures, and sells technologies, products, and services used in research, discovery, and preclinical testing. Harvard Bioscience’s offerings support a broad range of laboratory workflows, including cellular and molecular biology, electrophysiology, physiological measurement, data acquisition, and bioproduction. Its product portfolio serves academic institutions, pharmaceutical and biotechnology companies, contract research organizations, and government laboratories worldwide. The company’s current business is organized around specialized platforms for research instrumentation and preclinical systems, helping scientists generate and analyze data across drug discovery, therapy development, and laboratory experimentation. With operations and sales reach across major global markets, Harvard Bioscience holds a focused role in the life sciences tools sector as a supplier of precision instruments and related consumables for scientific and biomedical research.
CEO Mr. John Duke · 316 employees · United States · https://www.harvardbioscience.com
